Interestingly, ROR1 or ROR2 upregulation has been observed in many cancers: ROR1 is upregulated in solid tumors or hematologic malignancies while ROR2 is overexpressed in osteosarcomas or renal cell carcinomas (Rebagay et al., 2012). Here, ROR2 is linked to cancer.